Global Blood Therapeutics Priced, Nasdaq: GBT

Early-stage biotech developing a small molecule therapy for sickle cell disease.

Industry: Health Care

Latest Trade: $27.90 -0.80 (-2.8%)

First Day Return: +115.6%

Return from IPO: +43.5%

Industry: Health Care

We are a biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. We are developing our initial product candidate, GBT440, as a once-daily, oral prophylactic therapy for sickle cell disease and are currently evaluating GBT440 in both healthy subjects and SCD patients in a randomized, placebo-controlled, double-blind clinical trial that we characterize as a Phase 1/2 clinical trial. GBT440 targets the underlying mechanism of red blood cell sickling, which we believe provides the potential to treat SCD rather than only its associated symptoms. In addition to GBT440 for the treatment of SCD, we are leveraging our deep scientific expertise in the chemical and biological mechanisms of blood-based disorders to target hypoxemic pulmonary disorders and hereditary angioedema. We own rights to our product candidate portfolio in the United States, Europe and other major markets.
more less
IPO News for Global Blood Therapeutics
more
IPO Data
IPO File Date 07/08/2015
Offer Price $20.00
Price Range $16.00 - $18.00
Offer Shares (mm) 6.0
Deal Size ($mm) $120
IPO Data
IPO Date 08/11/2015
Offer Price $20.00
Price Range $16.00 - $18.00
Offer Shares (mm) 6.0
Deal Size ($mm) $120
Underwriters
more
Company Data
Headquarters South San Francisco, CA
Founded 2011
Employees 47
Website www.globalbloodtx.com